ENVB
Enveric Biosciences, Inc.
+0.08 (+5.70%)1.58USD107K成交股數7.0M市值–本益比(近四季)–股價營收比+121.2%營收年增(近四季)–下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | −292.00+121% | −303.00-15250% | −250.00+15% | 274.00-883% | −132.00-119% | 2.00-100% | −217.00-110% | −35.00-104% | 696.00 | 566.00 | 2K | 916.00 |
| 營業成本 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利率 | – | – | – | – | – | – | – | – | – | – | – | – |
| 研發費用 | 1.4M | 346K | 372K | 402K | 1.3M | 746K | 803K | 565K | 506K | 1.7M | 1.3M | 2.4M |
| 銷售管理費用 | 1.6M | 1.2M | 1.8M | 1.4M | 1.2M | 1.4M | 1.2M | 1.2M | 1.9M | 550K | 2.1M | 3.3M |
| 營業利益 | −3.0M+20% | −1.6M-25% | −2.2M+5% | −1.9M-1% | −2.5M+2% | −2.2M-8% | −2.1M-40% | −1.9M-67% | −2.5M | −2.4M | −3.4M | −5.8M |
| 營業利益率 | 1,036,794.9% | 539,000.0% | 877,569.2% | -683,920.8% | 1,908,370.5% | -109,376,650.0% | 959,996.3% | 5,422,660.0% | -355,936.4% | -421,265.0% | -154,152.7% | -628,275.9% |
| 稅後淨利 | −3.0M+20% | −1.6M-25% | 18.7M-996% | −1.9M-0% | −2.5M+3% | −2.2M-107% | −2.1M-26% | −1.9M-70% | −2.5M | 31.4M | −2.8M | −6.4M |
| 淨利率 | 1,036,894.9% | 539,100.0% | -7,471,126.4% | -683,820.8% | 1,908,470.5% | -109,248,300.0% | 960,383.4% | 5,369,697.1% | -353,005.0% | 5,539,893.3% | -126,160.8% | -693,892.2% |
| 稀釋 EPS | -0.76-93% | -1.08-93% | 0.80-102% | -10.81+191% | -11.65+26% | -14.58-87% | -43.10+3215% | -3.72+22% | -9.21 | -114.64 | -1.30 | -3.04 |
| 稀釋股數 | 4.0M | 1.5M | 335K | 313K | 216K | 150K | 48.4K | 506K | 267K | 144K | 2.2M | 2.1M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | – | – | – | – | – | – | – | – | – | – | – | – |
| 應收帳款 | – | – | – | – | – | – | – | – | – | – | – | – |
| 存貨 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總資產 | 8.9M | 5.5M | 5.1M | 4.4M | 3.5M | 5.1M | 4.8M | 6.1M | 8.8M | 4.3M | 6.6M | 9.8M |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 股東權益 | 8.1M | 5.1M | 4.2M | 3.5M | 2.2M | 3.9M | 4.0M | 5.4M | 6.5M | 2.0M | 2.4M | 4.9M |
| 負債比 | – | – | – | – | – | – | – | – | – | – | – | – |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −2.3M-6% | – | – | – | −2.4M | – | – | −2.6M | – | – | – |
| 資本支出 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流 | – | – | – | – | – | – | – | – | – | – | – | – |
| 折舊攤銷 | 37K | 37K | 39K | 40K | 40K | 81K | 85K | 85K | 85K | 85K | 86K | 87K |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | – | – | – | – | – | – | – | – | – | – | – |
營收拆解
這家公司的 XBRL 沒有標分部、產品或地區營收。多半是單一業務,或只在 10-K 文字裡揭露。
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | −106.00 | -148.4% | 12.1M | -11,415,094.3% | -36.24 | – |
| FY2024 | 219.00 | -94.1% | 9.6M | 4,383,561.6% | -228.48 | – |
| FY2023 | 4K | -170.6% | 17.5M | 471,952.5% | -121.29 | −14.1M |
| FY2022 | −5K | – | −18.5M | 351,901.9% | -13.00 | −17.7M |
| FY2021 | – | – | −49.0M | –% | -2.07 | −11.6M |
| FY2020 | – | – | −6.9M | –% | -1.19 | – |
| FY2019 | 39.9M | -7.2% | −2.4M | -6.0% | -2.83 | – |
| FY2018 | 43.0M | – | −16.9M | -39.3% | -20.47 | – |